A Performance Analysis of the Peritoneal Ultrafiltration (PUF) Achieved With the Carry Life® UF

NCT ID: NCT03724682

Last Updated: 2019-08-28

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 8 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2019-03-01
• Study Completion Date: 2019-06-26

Brief Summary

The Carry Life UF device performs peritoneal ultrafiltration by adding a concentrated glucose to peritoneal dialysis fluid which has been instilled into the abdomen prior to the connection of the device. Maintaining the glucose concentration in the intraperitoneal fluid results in an increased fluid removal (ultrafiltration).

The clinical investigation will evaluate the ultrafiltration achieved with the Carry Life UF device compared to standard peritoneal dialysis (PD) therapy

Detailed Description

A study of the peritoneal ultrafiltration achieved with Carry Life® UF compared to standard PD therapy, performed in 12 stable PD patients. The study consists of one baseline study session with Icodextrin overnight and one four-hour, 2.27% glucose exchange and three Carry Life® UF treatments with different glucose doses. All treatments are preceded by an Icodextrin dwell overnight.

Visit 1: The patient will be screened for study eligibility and a signed informed consent obtained before any of the study activities commence. Once included in the study the patient will be asked to document their ultrafiltration volumes for the week prior to the baseline study session (PD bags to be weighed before and after).

Visit 2: Baseline study session with standard PD therapy. The evening before visit 2 the patient will use Icodextrin 2000 ml overnight which is drained at the clinic before the start of the second PD exchange.

• A four-hour dwell with 2.27%, 2000 ml PD fluid will be performed at the clinic.
• During the study sessions the fluid intake and output will be measured.
• A 24 h urine collection for urea and creatinine clearance started the day before the baseline study session will be completed at the baseline study session.

Visit 3, 4 and 5: Carry Life® UF study sessions The evening before the visits the patient will use Icodextrin 2000 ml overnight which is drained at the clinic the next day before the start of the Carry Life® UF study session.

• The Carry Life UF study session starts with filling the peritoneal cavity with 1500 ml of a standard glucose-based PD solution of 1.36%.
• The Carry Life® UF is then connected to the PD catheter and the 5-hour treatment starts. The glucose dose for visit 3 is 11 g/h, visit 4, 14 g/h and visit 5, 20 g/h.
• During the treatment, IP fluid will be drained hourly and as required.
• During the study sessions the fluid intake and output will be measured.
• During and after each study session the patient's tolerability of the treatment will be evaluated by monitoring vital signs (blood pressure and heart rate hourly).
• Evaluation of the patient's experience of the Carry Life® UF treatment is documented in the CRF, regarding the sensation of the flow in and out of the abdomen and a short questionnaire between visit 4 and 5, regarding the usability and experience of the device.

Follow-up: Follow-up will be performed after the completion of the Carry Life® UF study sessions. The follow-up can either be performed at the clinic or by telephone which is at the discretion of the investigator and the patient.

Conditions

Chronic Renal Failure

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Single arm

Single arm in which everyone enrolled in a trial receives treatment with Carry Life UF device,

Group Type: EXPERIMENTAL

Carry Life UF device

Intervention Type: DEVICE

Treatment with the Carry Life UF device compared to standard PD therapy

Interventions

Carry Life UF device

Treatment with the Carry Life UF device compared to standard PD therapy

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

• Age ≥ 18 years
• Male or female
• On stable PD including Icodextrin, treated at the clinic for at least 3 months
• No clinical signs of dehydration.
• Obtained written consent to participate in the study

Exclusion Criteria

• Significant illness or active infection (evaluated by clinical examination) in the past 4 weeks
• Episodes of peritonitis during the past 2 months
• Active malignant disease
• Diabetes type 1
• Abdominal hernias
• HIV and/or hepatitis positive within the last 3 months
• Known pregnancy or breastfeeding and pregnancy test for women of child bearing age.
• Conditions deemed by investigator as inappropriate for participation
• Participation in clinical trials, interfering with the present study, one month prior to inclusion

• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Triomed AB

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Ann-Cathrine Johansson

Role: PRINCIPAL_INVESTIGATOR

Renal Unit, Skånes Universitetssjukhus, Malmö

Locations

Skånes Universitetssjukhus, Malmö

Malmo, Skåne County, Sweden

Skånes Universitetssjukhus, Lund

Lund, , Sweden

Karolinska Universitetssjukhuset

Stockholm, , Sweden

Countries

Sweden

References

Heimburger O, Hegbrant J, Martus G, Wilkie M, De Leon C, Carlsson O, Johansson AC. Effects of Steady Glucose Concentration Peritoneal Dialysis on Ultrafiltration Volume and Sodium Removal: A Pilot Crossover Trial. Clin J Am Soc Nephrol. 2024 Feb 1;19(2):224-232. doi: 10.2215/CJN.0000000000000342. Epub 2023 Oct 30.

Reference Type: DERIVED

PMID: 37902732 (View on PubMed)

Other Identifiers

Tmed-007 (Malmö)

Identifier Type: -

Identifier Source: org_study_id